scholarly article | Q13442814 |
P50 | author | Andrew Badley | Q43134987 |
Nathan W Cummins | Q88334168 | ||
Sekar Natesampillai | Q117792587 | ||
P2093 | author name string | Scott Kaufmann | |
Fatma Aboulnasr | |||
Amy M Sainski-Nguyen | |||
P2860 | cites work | Bcl-2 maintains B cell memory | Q24308796 |
Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells | Q24599011 | ||
Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin | Q24676673 | ||
Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant | Q27323780 | ||
BH3-only proteins: a 20-year stock-take | Q28085220 | ||
Activation of the NF-kappaB pathway by caspase 8 and its homologs | Q28139456 | ||
HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation | Q28211642 | ||
Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation | Q28248512 | ||
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation | Q29619611 | ||
Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication | Q33332152 | ||
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Q33438494 | ||
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation | Q33508788 | ||
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. | Q33566570 | ||
Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2 | Q37356313 | ||
A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia | Q37577524 | ||
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. | Q38398064 | ||
HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand | Q38457134 | ||
The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane | Q38668186 | ||
A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation. | Q38834329 | ||
HIV-1 protease-induced apoptosis | Q38989333 | ||
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies | Q38996888 | ||
Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells | Q39090535 | ||
Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size | Q39599213 | ||
Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy | Q39748924 | ||
Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study | Q40668686 | ||
U937 cells overexpressing bcl-xl are resistant to human immunodeficiency virus-1-induced apoptosis and human immunodeficiency virus-1 replication | Q40965823 | ||
The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication | Q41125440 | ||
bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation | Q41964290 | ||
Activation of Bcl-2 promoter-directed gene expression by the human immunodeficiency virus type-1 Tat protein | Q45749420 | ||
The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells | Q45788521 | ||
The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+ T Cells. | Q50740811 | ||
Down-regulation of IL-7Ralpha expression in human T cells via DNA methylation. | Q51976103 | ||
A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. | Q53582191 | ||
Transcriptional regulation of the HIV-1 promoter by NF-kappa B in vitro | Q68111216 | ||
IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: correlation with its ability to block culture-induced down-modulation of Bcl-2 | Q71727879 | ||
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. | Q33823310 | ||
Intracellular Casp8p41 content is inversely associated with CD4 T cell count | Q34004148 | ||
Human immunodeficiency virus envelope protein Gp120 induces proliferation but not apoptosis in osteoblasts at physiologic concentrations. | Q34024085 | ||
Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity | Q34150316 | ||
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases | Q34539993 | ||
Bcl-2 upregulation by HIV-1 Tat during infection of primary human macrophages in culture | Q34577364 | ||
HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells | Q34672568 | ||
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. | Q34985945 | ||
Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells | Q35111879 | ||
The HIV-1-specific protein Casp8p41 induces death of infected cells through Bax/Bak | Q35140447 | ||
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells | Q35202343 | ||
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis | Q35543827 | ||
HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. | Q35661660 | ||
In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice | Q35760429 | ||
Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection | Q35837788 | ||
bc1-2 expression facilitates human immunodeficiency virus type-1 mediated cytopathic effects during acute spreading infections | Q35864541 | ||
Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo | Q35914355 | ||
Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy | Q35965172 | ||
Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch | Q36125264 | ||
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection | Q36225040 | ||
The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS | Q36400220 | ||
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy | Q36481572 | ||
Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo | Q36607484 | ||
Interleukin-7 promotes HIV persistence during antiretroviral therapy | Q36873277 | ||
Persistent HIV-1 replication maintains the tissue reservoir during therapy | Q36897321 | ||
Analysis of HIV Protease Killing Through Caspase 8 Reveals a Novel Interaction Between Caspase 8 and Mitochondria | Q36901485 | ||
HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells | Q36901499 | ||
Altering cell death pathways as an approach to cure HIV infection | Q37062057 | ||
Negative Feedback Regulation of HIV-1 by Gene Editing Strategy | Q37177251 | ||
Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab). | Q37312736 | ||
Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppres | Q37347313 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P577 | publication date | 2017-03-22 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition | |
P478 | volume | 91 |
Q88866382 | Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells |
Q41930599 | Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins |
Q89574422 | BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo |
Q92637590 | Block-And-Lock Strategies to Cure HIV Infection |
Q47555333 | Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV. |
Q52324513 | HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome. |
Q41921236 | HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim. |
Q92857802 | Have Cells Harboring the HIV Reservoir Been Immunoedited? |
Q52571192 | Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. |
Q47550536 | Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. |
Q97067038 | Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening |
Q47566696 | Recent progress in understanding HIV reservoirs |
Q92537912 | Specific Biological Features of Adipose Tissue, and Their Impact on HIV Persistence |
Q92300043 | Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs |
Q90211132 | Telomerase Biology Associations offer Keys to Cancer and Aging Therapeutics |
Search more.